Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering
January 29 2020 - 4:01PM
Business Wire
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,”
“we,” “our,” or “us”) (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that it intends to offer
its securities in an underwritten public offering. The proposed
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Oppenheimer & Co. Inc. is acting as sole underwriter for the
offering.
Catabasis intends to use the net proceeds from the offering for
clinical trial and other research and development activities;
initial commercialization preparations; and for working capital and
other general corporate purposes.
The securities described above will be offered pursuant to a
shelf registration statement on Form S-3 (No. 333-231441), which
was previously filed with and declared effective by the Securities
and Exchange Commission (“SEC”) on May 23, 2019. A preliminary
prospectus supplement and accompanying base prospectus relating to
and describing the terms of the offering will be filed with the SEC
and will be available on the SEC’s website located at
http://www.sec.gov, copies of which may be obtained, when
available, from Oppenheimer & Co. Inc. Attention: Syndicate
Prospectus Department, 85 Broad St., 26th Floor, New York, NY
10004, by telephone at (212) 667-8055 or by email at
EquityProspectus@opco.com. The final terms of the offering will be
disclosed in a final prospectus supplement to be filed with the
SEC.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Catabasis At Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our lead program is edasalonexent, an NF-kB inhibitor in
Phase 3 development for the treatment of Duchenne muscular
dystrophy.
Forward Looking Statements Any statements in this press
release about future expectations, plans and prospects for the
Company, including statements about the anticipated public offering
and the anticipated use of net proceeds therefrom, among other
things, statements containing the words “believes,” “anticipates,”
“plans,” “expects,” “may” and similar expressions, constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The offering is subject
to market and other conditions and there can be no assurance as to
whether or when the offering may be completed or as to the actual
size or terms of the offering. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, including: market conditions that may
affect the timing, terms and conditions of the offering, the
Company’s ability to satisfy the conditions to closing of the
offering and other matters affecting our ability to consummate the
offering on terms acceptable to us. In addition, the
forward-looking statements included in this press release represent
the Company’s views as of the date of this press release. The
Company anticipates that subsequent events and developments will
cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in
the future, the Company specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200129005689/en/
Investor and Media Contact Andrea
Matthews Catabasis Pharmaceuticals, Inc. T: (617) 349-1971
amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2023 to Apr 2024